Treatment for refractory or relapsing TTP includes vincristine, a second-line therapy with an unknown mechanism of action. Vincristine is occasionally given to treat resistant cases, but has no proven benefit. Supportive care for end-organ damage may be required. Hemodialysis is occasionally required for renal failure. Anticonvulsants, such as phenytoin, may be required to control seizures.
Platelet transfusion is contraindicated since it is associated with rapid deterioration.
The platelet aggregation worsens with platelet transfusions. In some studies, extensive platelet aggregates were found throughout the central nervous system postmortem. The differential diagnosis is extensive for thrombocytopenia, but early recognition of TTP is essential for the patient's survival. The goal of therapy is to reduce destruction of platelets. Glucocorticoid - Used for immunosuppressant activity.